Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.00 – $0.04
0% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.3M | $4.9M | $3.5M | $2.0M | $3.6M | $4.9M | $9.9M | $5.5M |
| Cost of revenue | $356.0K | $353.5K | $412.9K | $386.7K | $400.7K | $405.6K | $277.9K | $277.6K |
| Gross profit | $2.9M | $4.5M | $3.1M | $1.6M | $3.2M | $4.5M | $9.9M | $5.5M |
| Gross margin | 89.2% | 92.7% | 88.3% | 80.5% | 89.0% | 91.7% | 100.0% | 100.0% |
| R&D | $7.7M | $10.9M | $5.5M | $2.4M | $8.2M | $8.9M | $15.5M | $12.3M |
| Operating income | −$9.6M | −$9.6M | −$8.9M | −$3.5M | −$9.1M | −$10.6M | −$12.8M | −$14.9M |
| EBITDA | −$5.9M | −$9.3M | −$8.2M | −$5.3M | −$12.7M | −$15.2M | −$12.9M | −$15.0M |
| Net income | −$6.2M | −$9.9M | −$5.3M | −$3.9M | −$9.5M | −$10.8M | −$13.0M | −$14.7M |
| Net margin | -188.8% | -203.3% | -151.6% | -197.3% | -260.9% | -220.0% | -131.3% | -268.4% |
| EPS (diluted) | -0.01 | -0.01 | -0.00 | -0.00 | -0.01 | -0.01 | -0.01 | -0.00 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $8M | $-0.00 | $-0.00–$-0.00 | 1 |
| 2027 | $7M | $-0.01 | $-0.01–$-0.01 | 1 |
| 2028 | $16M | $-0.01 | $-0.01–$-0.01 | 1 |
| 2029 | $23M | $-0.01 | $-0.01–$-0.01 | 1 |
Forward consensus · source: Financial Modeling Prep
ACTINOGEN MED LTD
No one on the platform currently holds ATGGF.
No tracked institution reports a position in ATGGF as of their last filing.
No one on the platform has traded ATGGF yet.
| $59M |
| — |
| NICXFNicox S.A. | $0.30 | +0.00% | $31M | — |
| PHYOFIXICO plc | $0.07 | +0.00% | $7M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 0.2× sales vs its 15.2× historical median P/S.
Fair value ≈ $0.08 · price $0.00 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.